SCHEMBL7064055

SCHEMBL7064055

O=C(O)C1(NS(=O)(=O)c2ccc3ccccc3c2)CCCCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
HTT P42858 1/20 0.62
PLG P00747 3/20 0.49
PLAU P00749 3/20 0.49
KAT6A Q92794 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
PLAT P00750 1/20 0.47
MMP1 P03956 2/20 0.47
MMP13 P45452 2/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 1/20 0.47
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46
LMNA P02545 2/20 0.45
F2 P00734 1/20 0.45
PRSS1 P07477 1/20 0.45
PRSS2 P07478 1/20 0.45
PRSS3 P35030 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1771259 0.87 MMP1 (0.62) USP2SMN1; SMN2HTTMMP1MMP13
SCHEMBL5675304 0.84 USP2 (0.60) USP2SMN1; SMN2HTTPLGPLAU
SCHEMBL8647470 0.84 KAT6A (0.49) USP2SMN1; SMN2HTTKAT6AL3MBTL1
SCHEMBL14676227 0.82 USP2 (0.58) USP2SMN1; SMN2HTTPLGPLAU
SCHEMBL7066967 0.82 HTT (0.59) USP2SMN1; SMN2HTTPLGPLAU
SCHEMBL7066448 0.81 MMP13 (0.62) USP2SMN1; SMN2HTTMMP1MMP13
SCHEMBL7062426 0.80 USP2 (0.79) USP2SMN1; SMN2HTTPLGPLAU
SCHEMBL14675849 0.79 USP2 (0.55) USP2SMN1; SMN2HTTPLGPLAU
SCHEMBL6987411 0.78 F2 (0.56) USP2SMN1; SMN2HTTPLGPLAU
SCHEMBL7065810 0.78 SMN1; SMN2 (0.55) USP2SMN1; SMN2HTTPLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP claimed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO claimed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 USP2 1089/4885SMN1; SMN2 324/4885HTT 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.